As researchers around the world work to advance solutions to combat COVID-19 and other diseases, we remain committed to manufacturing reagents that are critical to many of these important programs. We are here to support your efforts, and invite you to contact us if we can be of help in realizing current supply continuity plans, future business resumption efforts, or even to address routine product or technical questions. Reach out to us any time at info@BangsLabs.com
Molecular diagnostics
PCR-based tests look for viral genetic material (RNA) Magnefy, our ~1µm carboxylated superparamagnetic microspheres may be used for nucleic acid isolations. They offer high surface area and high surface titer with a rapid uniform magnetic response profile.
Catalog Number | Description | Product Data Sheet | Safety Data Sheet |
---|---|---|---|
MFY0002 | Magnefy™ • COOH 1µm | PDS 756.pdf | SDS MY100.pdf |
Rapid point-of-care (POC) immunoassays
Our highly-fluorescent europium (III) nanoparticles offer exceptional stability, in addition to well-functionalized carboxylated surfaces for the covalent attachment of ligand. Our Eu (III) nanoparticles have been used to develop highly sensitive assays (microplate, lateral flow) based on time-resolved (TRF) fluorescence and as particulate labels in chemiluminence assays.
Catalog Number | Description | Nominal Diameter | Specification Range | Product Data Sheet |
---|---|---|---|---|
FCEU001 | Europium Chelate PS - COOH | 0.10µm | 0.090 - 0.110µm | PDS 741.pdf |
FCEU002 | Europium Chelate PS - COOH | 0.20µm | 0.190 - 0.210µm | PDS 741.pdf |
FCEU003 | Europium Chelate PS - COOH | 0.30µm | 0.270 - 0.330µm | PDS 741.pdf |
FCEU004 | Europium Chelate PS - COOH | 0.40.µm | 0.370 - 0.430µm | PDS 741.pdf |
Cell Culture for Biotherapeutics & Vaccine Development
Our ViaCheck standards mimic the characteristics of live and dead cells may be used to validate cell viability analyzers. Our Quantum™ Flow Cytometry standards may be utilized to demonstrate transfection efficacy, and for cellular surface marker expression analysis.
Catalog Number | Description | Volume (mL) | Product Data Sheet | Safety Data Sheet |
---|---|---|---|---|
VC10B | ViaCheck™ 0% Viability Control | 20 | PDS 706.pdf | SDS ST352.pdf |
VC25B | ViaCheck™ 25% Viability Control | 20 | PDS 706.pdf | SDS ST352.pdf |
VC20B | ViaCheck™ 50% Viability Control | 20 | PDS 706.pdf | SDS ST352.pdf |
VC30B | ViaCheck™ 75% Viability Control | 20 | PDS 706.pdf | SDS ST352.pdf |
VC40B | ViaCheck™ 90% Viability Control | 20 | PDS 706.pdf | SDS ST352.pdf |
VC50B | ViaCheck™ 100% Viability Control | 20 | PDS 706.pdf | SDS ST352.pdf |
VC50N | ViaCheck™ Concentration Control (0.5 × 106) | 20 | PDS 711.pdf | SDS ST353.pdf |
VC60N | ViaCheck™ Concentration Control (1 × 106) | 20 | PDS 711.pdf | SDS ST353.pdf |
VC70N | ViaCheck™ Concentration Control (4 × 106) | 20 | PDS 711.pdf | SDS ST353.pdf |
VC80N | ViaCheck™ Concentration Control (8 × 106) | 20 | PDS 711.pdf |
Catalog Number | Description | Units | Product Data Sheet | Safety Data Sheet |
---|---|---|---|---|
VC10BSS | ViaCheck™ 0% Viability Control SingleShots™ | 25 or 75 | PDS 706.pdf | SDS ST352.pdf |
VC25BSS | ViaCheck™ 25% Viability Control SingleShots™ | 25 or 75 | PDS 706.pdf | SDS ST352.pdf |
VC20BSS | ViaCheck™ 50% Viability Control SingleShots™ | 25 or 75 | PDS 706.pdf | SDS ST352.pdf |
VC30BSS | ViaCheck™ 75% Viability Control SingleShots™ | 25 or 75 | PDS 706.pdf | SDS ST352.pdf |
VC40BSS | ViaCheck™ 90% Viability Control SingleShots™ | 25 or 75 | PDS 706.pdf | SDS ST352.pdf |
VC50BSS | ViaCheck™ 100% Viability Control SingleShots™ | 25 or 75 | PDS 706.pdf | SDS ST352.pdf |
VC50NSS | ViaCheck™ Concentration Control (0.5 × 106) SingleShots™ | 25 or 75 | PDS 711.pdf | SDS ST353.pdf |
VC60NSS | ViaCheck™ Concentration Control (1 × 106) SingleShots™ | 25 or 75 | PDS 711.pdf | SDS ST353.pdf |
VC70NSS | ViaCheck™ % Concentration Control (4 × 106) SingleShots™ | 25 or 75 | PDS 711.pdf | SDS ST353.pdf |
VC80NSS | ViaCheck™ % Concentration Control (8 × 106) SingleShots™ | 25 or 75 | PDS 711.pdf | SDS ST353.pdf |